New drug shows promise for fatty liver in small trial

NCT ID NCT00666016

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC STEATOHEPATITIS (NASH)

Contacts and locations

Locations

CHU AMIENS, Service d'Hépato-Gastroentérologie

Amiens, 80054, France
Centre Hospitalier de Hyères, Hôpital de Jour, Service d'Hépato-Gastro-Entérologie

Hyères, 83407, France
Groupe Hospitalier Pitié-Salpétrière - Sce Hépato-Gastroentérologie - 47-83 Bd de l'Hôpital

Paris, 75651, France
Hôpital Archet 2 - Pôle de Référence Hépatite C (Niveau -2) - 151, route Saint Antoine de Ginestière

Nice, 06200, France
Hôpital Saint Joseph, Service d'Hépato-Gastro-Entérologie

Marseille, 13285, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.